STOCKS TELEGRAPH

Tag: Salarius Pharmaceuticals Inc.

  • Salarius Pharmaceuticals Inc. (SLRX) Rebounds After Hours Following its Recent Downfall

    On March 15, Salarius Pharmaceuticals Inc. (SLRX) finally rebounded in the after-hours following its continued downfall after its latest earnings. The company had declared its 2021 financial results on March 10.

    Source: iStock

    During the regular trading session, the stock suffered a loss of 7.00% while the volume of shares exchanged remained above the average. The stock closed the session in the red at a price of $0.3441 per share. Following this, the stock rebounded in the after-hours to add a good 10.43%. Hence, SLRX stock was trading at a value of $0.3800 per share in the after-hours on Tuesday.

    The clinical-stage oncology company, Salarius Pharmaceuticals Inc. is based in Houston, TX. Currently, its 45.21 million outstanding shares trade at a market capitalization of $16.73 million.

    What Happened with SLRX?

    On March 10, the company reported its financial results for the fourth quarter and full-year 2021. Following this, the stock entered a downtrend which continued till March 15’s regular session. After plunging down for over 10.39% in the past five days, the stock finally rebounded and entered green in the after-hours on Tuesday. Since there is no recent news from the company, the downfall seems to be the reason for the comeback. In addition to external factors, it seems the low price was taken as a good buying opportunity by the investors.

    Presently, SLRX stock stands at a year-to-date loss of 30.57% while it subtracted a huge value of 77.06% in the past year.

    2021 Financial Results

    For Q4 2021, the company reported a net loss of 44.1 million against $1.8 million in the year-ago period. Therefore, the net loss per basic and diluted share was $0.09 and $0.10 in Q4 2021 and 2020, respectively.

    Moreover, the fiscal 2021 net loss was $12.8 million against $7.4 million for fiscal 2020. Thus, the net loss per basic and diluted share was $0.31 and $0.50 for fiscal 2021 and 2020, respectively.

    Furthermore, SLRX ended 2021 with cash, cash equivalents, and restricted cash of $29.2 million. This compares to $11.1 million at the end of fiscal 2020. The company expects the cash position to be enough to fund its operations through 2023.

    SLRX’s Recent Participations

    Recently, the company participated in the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference. SLRX’s CEO David Arthur, presented at the conference on February 24, 2022.

    Previously, Mr. Arthur also presented at the 2022 BIO CEO & Investor Conference which took place from February 14-17, 2022.

  • Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) is a leading late-stage biotherapeutics firm engaged in developing cancer therapeutics for oncology patients. The lead pipeline candidate of the company is Seclidemstat in Phase 1/2 clinical-stage used for treating prostate, breast, ovary cancer, and tumors.

    The price of SLRX stock during the regular trading of March 9, 2022, was $0.37 with a decline of 2.40%. At the last check of the aftermarket, the stock rebounded by 13.3%.

    SLRX: Events and Happenings

    On March 03, 2022, SLRX updated that it will release its financials for the three months ended December 31, 2021, on March 10, 2022. The company will also host a conference call and webcast to discuss its corporate matters. On February 17, 2022, SLRX reported its Executive management’s participation at the Virtual Diamond Equity Research Emerging Growth Invitational 2022 Conference on February 24.

    On February 08, 2022, SLRX announced its CEO’s virtual presence at the 2022 BIO CEO & Investor Conference held on February 14-17. On January 13, 2022, SLRX informed the press about its entry into a definitive contract with DeuteRx, LLC for the acquisition of a small molecule targeted protein degradation platform or SP-3164. On December 29, 2021, SLRX reported the achievement of a dosing milestone in seclidemstat Phase 1/2 trials. The company assessed its efficacy against Ewing sarcoma and FET-rearranged sarcomas and advanced to the second lead-in safety unit.

    SLRX: Key Financials

    On November 04, 2021, SLRX released its unaudited financial report for the third quarter of fiscal 2021 ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    No revenue was recorded by the company for Q3 2021, while a grant revenue of $1.37 million was reported during the same period of 2020.

    EPS

    Net loss per share basic and diluted in the third quarter of 2021 was $3.7 million, or $0.08 compared to $1.7 million, or $0.10 in the corresponding quarter of 2020. The company experienced a substantial incline in its earnings per share over the year.

    Conclusion

    SLRX stock price dipped 74% in the last year as the restrictions were imposed globally during the pandemic. The company’s stock rebounded in aftermarket trading as it is gearing for the fourth quarter financial statement release. The revenue guidance provided by the company for the quarter is $325 thousand against -$0.08 EPS.